Article | Published:

Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study

Primary Care Respiratory Journal volume 22, pages 161168 (2013) | Download Citation

Subjects

Abstract

Background:

Patient preference is an important factor when choosing an inhaler device for asthma or chronic obstructive pulmonary disease (COPD).

Aims:

To identify characteristics of patients with asthma or COPD who prefer a once-daily controller medication regimen.

Methods:

This retrospective observational study used electronic patient records and linked outcomes from patient-completed questionnaires in a primary care database. We compared the characteristics of patients indicating a preference for once-daily therapy with those who were unsure or indicating no preference.

Results:

Of 3,731 patients with asthma, 2,174 (58%) were women; the mean age was 46 years (range 2–94). Of 2,138 patients with COPD, 980 (46%) were women; the mean age was 70 years (range 35–98). Approximately half of the patients in each cohort indicated once-daily preference, one-quarter were unsure, and one-quarter did not prefer once-daily therapy. In patients with asthma or COPD, the preference for once-daily controller medication was significantly associated with poor adherence and higher concerns about medication. In asthma, good control and low self-perceived controller medication need were associated with once-daily preference. By contrast, in COPD, a high self-perceived need for controller medication was associated with once-daily preference. There was no significant relationship between once-daily preference and age, sex, disease severity, or exacerbation history.

Conclusions:

Understanding patient preferences may help prescribers to individualise therapy better for asthma and COPD.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003.

  2. 2.

    , . Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med 2010;362(17):1553–5.

  3. 3.

    , , , , . Persistence with asthma treatment is low in Germany especially for controller medication: a population based study of 483,051 patients. Allergy 2010;65(3):347–54.

  4. 4.

    , , , , . Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000;117(2):542–50.

  5. 5.

    , . Patient adherence in COPD. Thorax 2008;63(9):831–8.

  6. 6.

    , , , , , . Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin 2010;26(10):2421–9.

  7. 7.

    , , . The costs of asthma. Eur Respir J 1996;9(4):636–42.

  8. 8.

    , , , et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24.

  9. 9.

    , , , . Factors associated with medication nonadherence in patients with COPD. Chest 2005;128(5):3198–204.

  10. 10.

    , , , . Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011;105(3):454–60.

  11. 11.

    , , , et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102(12):1681–93.

  12. 12.

    . Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130(1 Suppl):65S–72S.

  13. 13.

    , , , et al. Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med 2007;7:8.

  14. 14.

    , , , , , . Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J 2011;37(5):982–5.

  15. 15.

    , , . The ADMIT series — Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010;19(1):10–20.

  16. 16.

    , , , et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364(18):1695–707.

  17. 17.

    , , , , , . Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010;10:1.

  18. 18.

    Optimum Patient Care. (accessed August 2012).

  19. 19.

    , , , . Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99(5):553–8.

  20. 20.

    , , , . Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir Med 2006;100(4):616–21.

  21. 21.

    National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. CG101. London: National Clinical Guideline Centre, 2010. (accessed August 2012).

  22. 22.

    National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. CG12. London: National Clinical Guideline Centre, 2004. (accessed August 2012).

  23. 23.

    Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. (accessed August 2012).

  24. 24.

    Clinical COPD Questionnaire. (accessed August 2012).

  25. 25.

    , , . Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011;6:289–96.

  26. 26.

    , , , , , . Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.

  27. 27.

    , , , . The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2(5147):257–66.

  28. 28.

    . The MRC breathlessness scale. Occup Med (Lond) 2008;58(3):226–7.

  29. 29.

    , , . The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14(1):1–24.

  30. 30.

    , . Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002;17(1):17–32.

  31. 31.

    , , , , . The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J 2009;18(4):300–5.

  32. 32.

    , . The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008;31(3):213–24.

  33. 33.

    , , , . The impact of parents' medication beliefs on asthma management. Pediatrics 2007;120(3):e521–6.

  34. 34.

    , , , et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res 2008;64(1):47–54.

  35. 35.

    , , , , . Impact of positive and negative beliefs about inhaled corticosteroids on adherence in inner-city asthmatic patients. Ann Allergy Asthma Immunol 2009;103(1):38–42.

  36. 36.

    , , , , , . Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study. J Asthma 2000;37(3):225–34.

Download references

Acknowledgements

Handling editor Maureen George

Statistical review Gopal Netuveli

We thank Annie Burden for her help with statistical analyses and Rob Horne for his input on the study design and analyses.

Funding The study was sponsored by GlaxoSmithKline. The funders had no role in the conduct of the study or interpretation of study results.

Author information

Affiliations

  1. Academic Centre of Primary Care, University of Aberdeen, UK

    • David Price
  2. Research in Real Life, Cambridge, UK

    • David Price
    • , Erika J Sims
    • , Linda Kemp
    • , Elizabeth V Hillyer
    • , Alison Chisholm
    •  & Julie von Ziegenweidt
  3. Division of Applied Health Sciences, University of Aberdeen, UK

    • Amanda J Lee
  4. Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK

    • Erika J Sims
  5. GlaxoSmithKline R&D, Uxbridge, UK

    • Angela Williams
  6. MedImmune, Cambridge, UK

    • Angela Williams

Authors

  1. Search for David Price in:

  2. Search for Amanda J Lee in:

  3. Search for Erika J Sims in:

  4. Search for Linda Kemp in:

  5. Search for Elizabeth V Hillyer in:

  6. Search for Alison Chisholm in:

  7. Search for Julie von Ziegenweidt in:

  8. Search for Angela Williams in:

Contributions

DP, EJS, and AW conceived and designed the study. LK conducted the analyses, with help from JvZ and AJL. EVH wrote the initial draft of the paper. All authors contributed to the interpretation of the data, writing of the manuscript, and review of the final draft. DP is the study guarantor.

Competing interests

DP has consultant arrangements with Almirral, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Medapharma, Novartis, Napp, Nycomed, Pfizer, Sandoz, and Teva. He or his research team have received grants and support for research in respiratory disease from the following organisations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Orion, Pfizer, and Teva. He has spoken for Almirral, AstraZeneca, Activaero, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Novartis, Merck, Mundipharma, Pfizer, and Teva. He has shares in AKL Ltd which produces phytopharmaceuticals. He is the sole owner of Research in Real Life Ltd and its subsidiary social enterprise Optimum Patient Care. AJL receives ad hoc payment for statistical consultancy with RIRL. EJS and JvZ are employees of RiRL. EVH is a consultant to RiRL and has done freelance writing work for Merck, Aerocrine, and TevaFrance. At the time this study was conducted, LK and AC were employees of RiRL and AW was an employee of GSK R&D.

Corresponding author

Correspondence to David Price.

Appendices

Appendix. STROBE Statement—Checklist for cohort studies — Price D, et al. Characteristics of patients preferring once-daily controller therapy for asthma and chronic obstructive pulmonary disease: retrospective observational study

About this article

Publication history

Received

Revised

Revised

Accepted

Published

DOI

https://doi.org/10.4104/pcrj.2013.00017

Further reading